{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:30:41Z","timestamp":1793413841416,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["KCXFZ20211020163811027"],"award-info":[{"award-number":["KCXFZ20211020163811027"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2307200"],"award-info":[{"award-number":["2023YFC2307200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12576-4","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:55:59Z","timestamp":1771952159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China"],"prefix":"10.1186","volume":"26","author":[{"given":"Liang","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaifang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peize","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hancheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"12576_CR1","volume-title":"Global tuberculosis report 2025","author":"World Health Organization","year":"2025","unstructured":"World Health Organization. Global tuberculosis report 2025. Geneva: World Health Organization; 2025."},{"issue":"4","key":"12576_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","volume":"5","author":"K Dheda","year":"2017","unstructured":"Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(4):291\u2013360.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"12576_CR3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMoa2400327","volume":"392","author":"L Guglielmetti","year":"2025","unstructured":"Guglielmetti L, Khan U, Vel\u00e1squez GE, et al. Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis. N Engl J Med. 2025;392(5):468\u201382.","journal-title":"N Engl J Med"},{"issue":"9","key":"12576_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S2213-2600(25)00194-8","volume":"13","author":"L Guglielmetti","year":"2025","unstructured":"Guglielmetti L, Khan U, Vel\u00e1squez GE, et al. Bedaquiline, delamanid, linezolid, and Clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. Lancet Respir Med. 2025;13(9):809\u201320.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"12576_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5588\/ijtld.17.0498","volume":"22","author":"A Tr\u00e9bucq","year":"2018","unstructured":"Tr\u00e9bucq A, Schwoebel V, Kuaban C, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis. 2018;22(1):17\u201325.","journal-title":"Int J Tuberc Lung Dis"},{"key":"12576_CR6","doi-asserted-by":"publisher","DOI":"10.2471\/B09458","volume-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment and care","author":"World Health Organization","year":"2025","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment and care. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"16","key":"12576_CR7","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","volume":"367","author":"M Lee","year":"2012","unstructured":"Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508\u201318.","journal-title":"N Engl J Med"},{"issue":"4","key":"12576_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","volume":"8","author":"Z Lan","year":"2020","unstructured":"Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020;8(4):383\u201394.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"12576_CR9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/ciad653","volume":"78","author":"T Hasan","year":"2024","unstructured":"Hasan T, Medcalf E, Nyang\u2019Wa B, et al. The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis. Clin Infect Dis. 2024;78(3):730\u201341.","journal-title":"Clin Infect Dis"},{"key":"12576_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijid.2021.08.055","volume":"111","author":"L Fu","year":"2021","unstructured":"Fu L, Weng T, Sun F, et al. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;111:138\u201347.","journal-title":"Int J Infect Dis"},{"key":"12576_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijid.2023.08.001","volume":"135","author":"L Fu","year":"2023","unstructured":"Fu L, Zhang X, Xiong J, et al. Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in china: a multicenter prospective cohort study. Int J Infect Dis. 2023;135:101\u20138.","journal-title":"Int J Infect Dis"},{"key":"12576_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2147\/IDR.S443897","volume":"17","author":"L Fu","year":"2024","unstructured":"Fu L, Wang W, Xiong J, et al. Evaluation of sulfasalazine as an adjunctive therapy in treating pulmonary pre-XDR-TB: efficacy, safety, and treatment implication. Infect Drug Resist. 2024;17:595\u2013604.","journal-title":"Infect Drug Resist"},{"key":"12576_CR13","volume-title":"Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17\u201319 November 2020","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17\u201319 November 2020. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"11","key":"12576_CR14","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1001\/archneur.60.11.1524","volume":"60","author":"RH Dworkin","year":"2003","unstructured":"Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60(11):1524\u201334.","journal-title":"Arch Neurol"},{"issue":"6","key":"12576_CR15","first-page":"83","volume":"115","author":"C Sommer","year":"2018","unstructured":"Sommer C, Geber C, Young P, et al. Polyneuropathies Dtsch Arztebl Int. 2018;115(6):83\u201390.","journal-title":"Polyneuropathies Dtsch Arztebl Int"},{"issue":"8","key":"12576_CR16","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3201\/eid2608.191499","volume":"26","author":"M Jaspard","year":"2020","unstructured":"Jaspard M, Butel N, El Helali N, et al. Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France. Emerg Infect Dis. 2020;26(8):1792\u2013800.","journal-title":"Emerg Infect Dis"},{"key":"12576_CR17","doi-asserted-by":"publisher","first-page":"908584","DOI":"10.3389\/fneur.2022.908584","volume":"13","author":"S Bano","year":"2022","unstructured":"Bano S, Nawaz A, Numan A, et al. A case report and literature review of the outcome of linezolid-induced optic and peripheral neuropathy in patients with multidrug-resistant pulmonary TB. Front Neurol. 2022;13:908584.","journal-title":"Front Neurol"},{"issue":"9","key":"12576_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"12576_CR19","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/jac\/dkac019","volume":"77","author":"S Wasserman","year":"2022","unstructured":"Wasserman S, Brust JCM, Abdelwahab MT, et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J Antimicrob Chemother. 2022;77(4):1146\u201354.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"12576_CR20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/pharmaceutics16060818","volume":"16","author":"RH Chen","year":"2024","unstructured":"Chen RH, Burke A, Cho JG, et al. New Oxazolidinones for tuberculosis: are novel treatments on the horizon? Pharmaceutics. 2024;16(6):818.","journal-title":"Pharmaceutics"},{"issue":"11","key":"12576_CR21","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1473-3099(25)00213-0","volume":"25","author":"N Heinrich","year":"2025","unstructured":"Heinrich N, Manyama C, Koele SE, et al. Sutezolid in combination with bedaquiline, delamanid, and Moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial. Lancet Infect Dis. 2025;25(11):1208\u201318.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"12576_CR22","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S1473-3099(25)00289-0","volume":"25","author":"LT Minja","year":"2025","unstructured":"Minja LT, van der Feltz I, Manyama C, et al. Delpazolid in combination with bedaquiline, delamanid, and Moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial. Lancet Infect Dis. 2025;25(11):1219\u201329.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12576-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12576-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12576-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:59:43Z","timestamp":1774965583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12576-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12576"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12576-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines. The study was approved by institutional review boards at participating centres, and all participants provided written informed consent. The study is registered at ChiCTR2000032298 on April 25, 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this work, the authors used ChatGPT and DeepSeek for language refinement and statistical code writing. No AI was used to generate any original data. After using these tools, all authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"686"}}